|
|
|
| CDMO Services: Customized Lipids & LNP Solutions | Bringing your lipid-based therapies from early research into clinical and commercial manufacturing demands more than technical capability. It requires experience, flexibility, and seamless execution across development stages. Explore GMP-ready, fully connected CDMO services: From lipid manufacturing through LNP formulation, manufacturing, and Fill & Finish. In this infographic, you will discover flexible collaboration models tailored to your path, pace, and evolving program needs. Download now to learn more! |
|
|
|
|
By Anna Rose Welch, Advancing RNA | Earlier this year, I attended the OPT Congress, where I had the great fortune of meeting consultant Marc Lemaitre. I recently sat down with Lemaitre for a follow-up interview to gauge some of the evolutions he’s been watching within the CMC landscape for oligo development. Here, he digs into the shifts in quality he’s noted, pointing out some of the potential pitfalls we may encounter in our manufacturing that could stand to impact the overall quality of our oligos. | |
|
|
|
By Jyotsna Jajula, Wayne State University | The significance of programmable nanomedicines is not simply that nanoparticles can carry more functions. It is that biological information can become part of the control logic. | |
|
|
|
By William Soliman, Ph.D., BCMAS | The RNA field is producing extraordinary volumes of information. Yet, giving an AI system access to more information does not necessarily make the system more scientifically intelligent. | |
|
|
|
By Advancing RNA Live | Though we may have increasingly clear understandings of our mRNA-LNP products structurally, understanding our products’ cellular function remains challenging without extensive clinical data. Here, this Advancing RNA panel featuring AbbVie’s Elaine Peters, Tessera’s Ilya Shestopalov, and Sanofi’s Philippe Talaga addresses what innovation — both in research and method development — can help us get more functional information about our molecules as we wait for more clinical development. | |
|
|
|
|
| Nucleic Acid-LNP Ultrafiltration And Diafiltration | White Paper | Recipharm Advanced Bio | Downstream filtration can make or break LNPs at scale. See how membrane format, loading, and shear affect recovery and stability — and how alternative TFF lowers scale‑up risk. |
|
|
| Minimizing Volume Requirements, Turnaround Time For Compendial Testing | Poster | By Steven J. Henry, Ph.D., Alexander Chiappini, Stacie Fichthorn, et al., Eurofins | Effectively applying compendial testing to cell and gene therapy products requires strategic test ordering and specialized micro-equipment to manage limited volume and accelerate turnaround time. |
|
|
|
| The Evolution Of Nucleotide Production | Article | Roche CustomBiotech | From harsh chemicals to gentle enzymes: discover the groundbreaking shift in nucleotide synthesis, making drug manufacturing cleaner, greener, and more efficient. |
|
|
|
|
|
|
|
| Webinar: Connecting the World of Oligonucleotide R&D With Early Clinical Scale Manufacturing | Moving oligonucleotide production from R&D to early clinical manufacturing brings new challenges in quality, scalability, process development, and equipment. This webinar explores a requirements-driven approach to oligonucleotide manufacturing, from solid-phase synthesis through scale-up, and highlights advances in synthesizer technology. Gain practical insights into building robust, reproducible processes that support pharmaceutical development and manufacturing at clinical scale. Click here to learn more. |
|
|
|
|
|
|
.png){kind=logo}
